Atrium Therapeutics, Inc.

RNA Nasdaq SEC CIK 2093101
Follow Atrium Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $15.3M +24.2% vs same quarter last year
Net income −$4.3M −11429.7% vs same quarter last year
EPS, diluted −$0.25
Operating cash flow −$25.4M −2339% vs same quarter last year
Revenue by quarter
$1.6M
$3.8M
$12.3M
$19.6M
$3M
$15.3M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing